Checkpoint Capital L.P. Acquires Shares of 25,543 Disc Medicine, Inc. (NASDAQ:IRON)

Checkpoint Capital L.P. acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON) during the third quarter, Holdings Channel.com reports. The firm acquired 25,543 shares of the company’s stock, valued at approximately $1,255,000. Disc Medicine comprises 0.6% of Checkpoint Capital L.P.’s holdings, making the stock its 14th biggest holding.

Several other institutional investors have also recently made changes to their positions in IRON. Amalgamated Bank boosted its holdings in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares during the period. Quest Partners LLC purchased a new stake in shares of Disc Medicine in the third quarter worth about $131,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Disc Medicine during the second quarter worth about $129,000. Finally, Quantbot Technologies LP purchased a new position in Disc Medicine during the third quarter valued at approximately $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Insider Transactions at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider William Jacob Savage sold 14,183 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $65.45, for a total value of $928,277.35. Following the transaction, the insider now directly owns 40,405 shares in the company, valued at $2,644,507.25. This trade represents a 25.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,879 shares of company stock valued at $1,912,335 over the last 90 days. 4.24% of the stock is currently owned by corporate insiders.

Disc Medicine Trading Down 1.7 %

IRON stock opened at $63.45 on Monday. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60. The business’s 50-day moving average is $54.05 and its 200 day moving average is $47.37. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -15.94 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15. As a group, equities analysts forecast that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on IRON shares. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Scotiabank raised their price target on shares of Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 5th. Jefferies Financial Group began coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $83.00 target price (up from $75.00) on shares of Disc Medicine in a research note on Tuesday, November 12th. Finally, HC Wainwright lifted their price target on Disc Medicine from $70.00 to $118.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $85.80.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.